Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

We recently compiled a list of the 12 Best Long-Term Stocks to Buy According to Ken Fisher. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion ...

UPDATED: Thursday, Jan. 16 at 10:25 a.m. ET Eli Lilly's Omvoh has picked up its second major FDA nod. After the IL-23 inhibitor's approval in 2023 to treat ulcerative colitis, the agency has now ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...